← Eichor
Condition: Gastric Junction Adenocarcinoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Gastric Junction Adenocarcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

T-Dxd in Combination With Ramucirumab as HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Phase 1/Phase 2 · 1 location(s) · Yonsei University · NCT05894824Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
Phase 2 · 11 location(s) · RemeGen Co., Ltd. · NCT06155383A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 47 location(s) · Bristol-Myers Squibb · NCT04895709At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Phase 2 · 2 location(s) · Mayo Clinic · NCT05969860Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric
Phase 2 · 2 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06560528Study of IBI363 in Patients with Advanced First-line Gastric Cancer
Phase 1 · 1 location(s) · Xiangdong Cheng · NCT06610799IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer
Phase 1/Phase 2 · 1 location(s) · Ruijin Hospital · NCT07025889Safety and Efficacy Study of Sorbitol With Neoadjuvant Chemotherapy Combined With Tirellizumab (PD-1 Inhibitor) in Patie
Phase 2/Phase 3 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06826079The Efficacy and Safety of LM-302 in Combination With Candonilimab and Capecitabine for First-Line Treatment in Patients
Phase 2 · 1 location(s) · Shanghai Zhongshan Hospital · NCT06587425Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative G
Phase 3 · 10 location(s) · Sun Yat-sen University · NCT05918094A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Phase 1 · 10 location(s) · Dren Bio · NCT06999187Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenoca
Phase 2 · 2 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT07102901Real-WorlD ZolbetUximab in Patients With HER-2 Negative and CLaudin 18.2 PosItive MetastatiC AdEnocarcinoma
Phase N/A · 1 location(s) · European Institute of Oncology · NCT07427992SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or M
Phase 3 · 1 location(s) · Shanghai Hengrui Pharmaceutical Co., Ltd. · NCT06649292Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastri
Phase 2 · 8 location(s) · Yu jiren · NCT05715931Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction
Phase 2 · 1 location(s) · Sixth Affiliated Hospital, Sun Yat-sen University · NCT04840264DBC-664 in Adult Patients With Solid Tumors
Phase 1 · 3 location(s) · Duboce Biopharmaceuticals, Inc. · NCT07705035A Study of KK2269 in Adult Participants With Solid Tumors
Phase 1 · 11 location(s) · Kyowa Kirin Co., Ltd. · NCT06266299Adjuvant Capecitabine Versus Observation Alone in Curatively Resected Stage IB Gastric Cancer((KCSG ST14-05): CATALYSIS
Phase 3 · 1 location(s) · Asan Medical Center · NCT01917552Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer
Phase 2 · 3 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07689851A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
Phase 1/Phase 2 · 1 location(s) · Akeso · NCT04982276Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First
Phase 1/Phase 2 · 51 location(s) · Merck Sharp & Dohme LLC · NCT06469944Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer
Phase 2 · 1 location(s) · Ruijin Hospital · NCT07026149Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta
Phase 3 · 286 location(s) · AstraZeneca · NCT07431281A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenoca
Phase 3 · 6 location(s) · Akeso · NCT07023315Immediate and Functional Results of Different Types of Reconstructions After Proximal Gastrectomy For Gastric and Esopha
Phase N/A · 1 location(s) · P. Herzen Moscow Oncology Research Institute · NCT07441785Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer
Phase 1/Phase 2 · 1 location(s) · West China Hospital · NCT05640609First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Phase 1 · 10 location(s) · Plexium, Inc. · NCT07284186XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT05494060QL1706 Combined With SOX Used in Theperioperative Treatment
Phase 1/Phase 2 · 1 location(s) · Xiangdong Cheng · NCT06766305
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.